01.13.25 -- Key Considerations For Early-Stage CGT Companies When Selecting A CDMO

By adopting unified digital platforms, implementing standardized data models, and enabling seamless system integrations, see how organizations can establish continuous digital threads.

Intensified adherent cell culture offers a promising solution to the limitations of traditional suspension culture, with the potential to improve efficiency, reduce costs, and accelerate development.

The manufacturing process for autologous therapies is complex and highly customized, requiring well-orchestrated transport, careful planning, and tight control of many discrete and manual processing steps.

Quality agreements serve a critical role within a CDMO-Sponsor partnership. Review the importance of aligning objectives, quality standards, and compliance frameworks to establish a robust foundation.

As you develop your future cell therapy drug, consider the risks and benefits of using autologous or allogeneic methods to best suit your development and manufacturing needs.

The first in a two-part series, this article focuses on how to move from candidate selection to a Phase 1 Investigational New Drug (IND) application.

Build a reliable, de-risked path to the clinic while avoiding unforeseen costs and compliance-related delays with advice from Suparna Sanyal, PhD, Head of Viral Vectors Commercial Development.

Immune cell therapies have incredible potential for cancer treatment, and making them more cost effective is a critical consideration for improving patient access and outcomes.

Gene editing makes off-the-shelf cell therapies feasible by modifying cells to evade immune attack, improve overall compatibility, and prolong the survival of transplanted cells.